CLEO Further Expands Ovarian Cancer Trial with Siles Health
Highlights
Prominent women’s ultrasound specialist Siles Health joins CLEO’s ovarian cancer trial
Inclusion of Siles will provide important insights to support clinical implementation strategies for market adoption of CLEO’s ovarian cancer blood test.
Further Expansion of Clinical Trials
CLEO has expanded its ovarian cancer Australian trial to include Siles Health network of 13 clinics across
Melbourne and regional Victoria. Siles Health is a prominent women’s health and ultrasound specialist,
with Associate Professor Charles Siles, acting as Principal Investigator. The collaborative partnership
aims to:
provide important insights into clinical workflows that will ultimately support clinical implementation strategies for successful market adoption of CLEO's ovarian cancer blood test;
supplement CLEO’s broader trial strategy by accessing a larger cohort of patient samples that may bolster the FDA-enabling U.S. trial;
continue to expand broader market awareness for CLEO; and
verify and optimise CLEO’s ovarian cancer blood test.
Commenting on the partnership, Associate Professor Charles Siles, Founder of Siles Health, said:
"The opportunity to collaborate with Cleo Diagnostics on their ovarian cancer diagnostics technology reflects our shared commitment to advancing women’s health. We see the unmet clinical need every day therefore we are genuinely excited that CLEO’s ovarian cancer blood test has the potential to positively impact women’s lives through accurate and early diagnosis.”
CLEO Chief Executive, Richard Allman, added:
“As we progress though our clinical trials initiatives, our focus continues on how this ultimately supports successful market adoption of CLEO's ovarian cancer blood test, specifically in the U.S. as our first market in the next year.
In this context, the partners that CLEO is engaging play an important role in how the Company is executing on its ambition to transform ovarian cancer diagnostics.”